Myriad Genetics (MYGN) Other Non-Current Assets (2010 - 2026)

Myriad Genetics (MYGN) has 15 years of Other Non-Current Assets data on file, last reported at $5.6 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $5.6 million, down 27.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.6 million (down 27.27% YoY), and the FY2025 annual result was $5.6 million, down 34.12% from the prior year.
• Other Non-Current Assets steadied at $5.6 million in Q1 2026 per MYGN's latest filing, from $5.6 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $22.1 million in Q2 2023 and troughed at $5.6 million in Q4 2025.
• A 5-year average of $11.4 million and a median of $8.8 million in 2022 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets soared 151.14% in 2023, then plunged 60.0% in 2025.
• A 5-year view of Other Non-Current Assets shows it stood at $15.5 million in 2022, then retreated by 0.65% to $15.4 million in 2023, then plunged by 44.81% to $8.5 million in 2024, then sank by 34.12% to $5.6 million in 2025, then changed by 0.0% to $5.6 million in 2026.
• Business Quant data shows MYGN's Other Non-Current Assets at $5.6 million in Q1 2026, $5.6 million in Q4 2025, and $6.6 million in Q3 2025.